Literature DB >> 11587488

Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery.

P Calvo1, B Gouritin, H Chacun, D Desmaële, J D'Angelo, J P Noel, D Georgin, E Fattal, J P Andreux, P Couvreur.   

Abstract

PURPOSE: The aim of this study was to evaluate the ability of long-circulating PEGylated cyanoacrylate nanoparticles to diffuse into the brain tissue.
METHODS: Biodistribution profiles and brain concentrations of [14C]-radiolabeled PEG-PHDCA, polysorbate 80 or poloxamine 908-coated PHDCA nanoparticles, and uncoated PHDCA nanoparticles were determined by radioactivity counting after intravenous administration in mice and rats. In addition, the integrity of the blood-brain barrier (BBB) after nanoparticles administration was evaluated by in vivo quantification of the diffusion of [14C]-sucrose into the brain. The location of fluorescent nanoparticles in the brain was also investigated by epi-fluorescent microscopy.
RESULTS: Based on their long-circulating characteristics, PEGylated PHDCA nanoparticles penetrated into the brain to a larger extent than all the other tested formulations. Particles were localized in the ependymal cells of the choroid plexuses, in the epithelial cells of pia mater and ventricles, and to a lower extent in the capillary endothelial cells of BBB. These phenomena occurred without any modification of BBB permeability whereas polysorbate 80-coated nanoparticles owed, in part, their efficacy to BBB permeabilization induced by the surfactant. Poloxamine 908-coated nanoparticles failed to increase brain concentration probably because of their inability to interact with cells.
CONCLUSIONS: This study proposes PEGylated poly (cyanoacrylate) nanoparticles as a new brain delivery system and highlights two requirements to design adequate delivery systems for such a purpose: a) long-circulating properties of the carrier, and b) appropriate surface characteristics to allow interactions with BBB endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11587488     DOI: 10.1023/a:1010931127745

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  23 in total

1.  Vector-mediated drug delivery to the brain.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1999-04-05       Impact factor: 15.470

Review 2.  Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means.

Authors:  R A Kroll; E A Neuwelt
Journal:  Neurosurgery       Date:  1998-05       Impact factor: 4.654

3.  Species difference in the disposition of liposomes among mice, rats, and rabbits: allometric relationship and species dependent hepatic uptake mechanism.

Authors:  H Harashima; S Komatsu; S Kojima; C Yanagi; Y Morioka; M Naito; H Kiwada
Journal:  Pharm Res       Date:  1996-07       Impact factor: 4.200

Review 4.  The blood-brain barrier: principles for targeting peptides and drugs to the central nervous system.

Authors:  D J Begley
Journal:  J Pharm Pharmacol       Date:  1996-02       Impact factor: 3.765

5.  Liposome targeting to mouse brain: mannose as a recognition marker.

Authors:  F Umezawa; Y Eto
Journal:  Biochem Biophys Res Commun       Date:  1988-06-30       Impact factor: 3.575

6.  Quantitative aspects of reversible osmotic opening of the blood-brain barrier.

Authors:  S I Rapoport; W R Fredericks; K Ohno; K D Pettigrew
Journal:  Am J Physiol       Date:  1980-05

7.  Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles.

Authors:  A E Gulyaev; S E Gelperina; I N Skidan; A S Antropov; G Y Kivman; J Kreuter
Journal:  Pharm Res       Date:  1999-10       Impact factor: 4.200

8.  Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles.

Authors:  R N Alyautdin; V E Petrov; K Langer; A Berthold; D A Kharkevich; J Kreuter
Journal:  Pharm Res       Date:  1997-03       Impact factor: 4.200

9.  Near infrared with principal component analysis as a novel analytical approach for nanoparticle technology.

Authors:  I Brigger; P Chaminade; D Desmaële; M T Peracchia; J d'Angelo; R Gurny; M Renoir; P Couvreur
Journal:  Pharm Res       Date:  2000-09       Impact factor: 4.200

10.  Brain drug delivery of small molecules using immunoliposomes.

Authors:  J Huwyler; D Wu; W M Pardridge
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

View more
  66 in total

1.  Development of transferrin functionalized poly(ethylene glycol)/poly(lactic acid) amphiphilic block copolymeric micelles as a potential delivery system targeting brain glioma.

Authors:  Wei-hua Ren; Jiang Chang; Cheng-hu Yan; Xiao-min Qian; Li-xia Long; Bin He; Xu-bo Yuan; Chun-sheng Kang; Didier Betbeder; Jing Sheng; Pei-yu Pu
Journal:  J Mater Sci Mater Med       Date:  2010-06-10       Impact factor: 3.896

Review 2.  New technologies for drug delivery across the blood brain barrier.

Authors:  A V Kabanov; E V Batrakova
Journal:  Curr Pharm Des       Date:  2004       Impact factor: 3.116

Review 3.  Treating metastatic cancer with nanotechnology.

Authors:  Avi Schroeder; Daniel A Heller; Monte M Winslow; James E Dahlman; George W Pratt; Robert Langer; Tyler Jacks; Daniel G Anderson
Journal:  Nat Rev Cancer       Date:  2011-12-23       Impact factor: 60.716

4.  Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

Authors:  A V Kabanov; H E Gendelman
Journal:  Prog Polym Sci       Date:  2007       Impact factor: 29.190

5.  Size mapping of electric field-assisted production of polycaprolactone particles.

Authors:  M Enayati; Z Ahmad; E Stride; M Edirisinghe
Journal:  J R Soc Interface       Date:  2010-06-02       Impact factor: 4.118

Review 6.  Nano-enabled delivery of diverse payloads across complex biological barriers.

Authors:  Kathleen A Ross; Timothy M Brenza; Andrea M Binnebose; Yashdeep Phanse; Anumantha G Kanthasamy; Howard E Gendelman; Aliasger K Salem; Lyric C Bartholomay; Bryan H Bellaire; Balaji Narasimhan
Journal:  J Control Release       Date:  2015-08-24       Impact factor: 9.776

Review 7.  Drug transport to brain with targeted nanoparticles.

Authors:  Jean-Christophe Olivier
Journal:  NeuroRx       Date:  2005-01

8.  A macrophage-nanozyme delivery system for Parkinson's disease.

Authors:  Elena V Batrakova; Shu Li; Ashley D Reynolds; R Lee Mosley; Tatiana K Bronich; Alexander V Kabanov; Howard E Gendelman
Journal:  Bioconjug Chem       Date:  2007-08-31       Impact factor: 4.774

9.  Recombinant Tissue Plasminogen Activator-conjugated Nanoparticles Effectively Targets Thrombolysis in a Rat Model of Middle Cerebral Artery Occlusion.

Authors:  Jun Deng; Heng Mei; Wei Shi; Zhi-Qing Pang; Bo Zhang; Tao Guo; Hua-Fang Wang; Xin-Guo Jiang; Yu Hu
Journal:  Curr Med Sci       Date:  2018-06-22

10.  Interaction of selegiline-loaded PLGA-b-PEG nanoparticles with beta-amyloid fibrils.

Authors:  Ipek Baysal; Samiye Yabanoglu-Ciftci; Yeliz Tunc-Sarisozen; Kezban Ulubayram; Gulberk Ucar
Journal:  J Neural Transm (Vienna)       Date:  2013-02-19       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.